Competitor Analysis: Toll-Like Receptor (TLR) Agonists & Antagonists

Publisher: La Merie Publishing
Pages: 178
Format: PDF
Product Line:
Competitor Analysis
Product Line:
Target Pipeline
Product Code: LMCA0082
Release Date: December of 2012

700.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Toll-Like Receptor (TLR) Agonists & Antagonists

Product description

The Competitive Intelligence Report Toll-Like Receptor (TLR) Agonists & Antagonists provides a competitor analysis in the development pipeline of novel small molecules, proteins, DNA, RNA and vaccines targeting the toll-like receptors (TLR) for treatment or prevention of cancer, infectious diseases, sepsis and allergy as of December 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Toll-like receptors (TLRs) are a class of proteins that play a key role in the innate immune system. TLRs have become attractive targets for activation or antagonism in pharmaceutical research. TLR agonists find use either alone or as adjuvants in combination with vaccine antigens. TLR antagonists are also under development for diseases with overwhelming immune response. Special attention has focused on the role of TLR agonists as novel adjuvants in prophylactic and therapeutic vaccines. They enhance dendritic cell function and their ability to prime T cells. Agonists that target toll-like receptors are being used clinically either alone or in combination with tumor antigens and showing initial success both in terms of enhancing immune responses and eliciting antitumor activity. TLR agonists and adjuvants are being investigated in a number of other therapeutic areas, such as in allergy, skin or infectious diseases.

The report includes a compilation of currently active projects in research and development of TLR agonists, antagonists, adjuvants and TLR-adjuvanted vaccines. In addition, the report lists company-specific R&D pipelines of TLR agonists and antagonists. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Therapeutic Area,
  • Product Category
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table of Contents

1. TLR Agonists – by Receptor Subtype
TLR2 Agonists
TLR3 Agonists
TLR4 Agonists
TLR5 Agonists
TLR7 Agonists
TLR7/8 Agonists
TLR8 Agonists
TLR9 Agonists
TLR Agonists unspecified

2. TLR Agonists – by Therapeutic Area
Infectious & toxicology
Neurology & psychiatry
Pulmonary & respiratory
Rheumatoid & autoimmune

3. TLR Antagonists – by Receptor Subtype
TLR2 Antagonists
TLR3 Antagonists
TLR4 Antagonists
TLR7/(8)/9 Antagonists
TLR Antagonists - unspecified

4. TLR Antagonists – by Therapeutic Area
Cardiovascula & acute care
Rheumatoid & autoimmune

5. TLR Adjuvants by Receptor Subtype
TLR3 Adjuvants
TLR2/4 Adjuvants
TLR4 Adjuvants
TLR7/8/9 Adjuvants
TLR9 Adjuvants
TLR Adjuvants - unspecified

6. TLR – Adjuvanted Vaccines – by Receptor Subtype
Vaccines adjuvanted with TLR3 agonist
Vaccines adjuvanted with TLR4 agonist
Vaccines adjuvanted with TLR5 agonist
Vaccines adjuvanted with TLR9 agonist
Vaccines adjuvanted with unspecified TLR agonist

7. TLR – Adjuvanted Vaccines – by Therapeutic Area
Prophylactic TLR-Adjuvanted Vaccines in Infectious Diseases
Therapeutic TLR3-Adjuvanted Vaccines in Oncology
Therapeutic TLR4-Adjuvanted Vaccines in Oncology
Therapeutic TLR4-Adjuvanted Vaccines in Pulmonary & Respiratory Diseases
Therapeutic TLR9-Adjuvanted Vaccines in Infectious Diseases
Therapeutic TLR9-Adjuvanted Vaccines in Neurology & Psychiatry
Therapeutic TLR9-Adjuvanted Vaccines in Oncology
Therapeutic TLR9-Adjuvanted Vaccines in Pulmonary & Respiratory
Therapeutic unspecified TLR-Adjuvanted Vaccines in Oncology
Therapeutic unspecified TLR-Adjuvanted Vaccines in Infectious Diseases

8. Corporate TLR Agonist & Antagonist R&D Portfolios

The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up